| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
| Products Intro: |
Product Name:Tipelukast
CAS:125961-82-2
Purity:Typically NLT 98%
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:Tipelukast
CAS:125961-82-2
|
|
| | Tipelukast Basic information |
| Product Name: | Tipelukast | | Synonyms: | tipelukast;KCA 757;MN 001 (pharMaceutical);4-[6-acetyl-3-[3-[(4-acetyl-3-hydroxy-2-propylphenyl)sulfanyl]propoxy]-2-propylphenoxy]butanoic acid;MN-001 (Tipelukast);Butanoic acid, 4-[6-acetyl-3-[3-[(4-acetyl-3-hydroxy-2-propylphenyl)thio]propoxy]-2-propylphenoxy]- | | CAS: | 125961-82-2 | | MF: | C29H38O7S | | MW: | 530.67282 | | EINECS: | | | Product Categories: | | | Mol File: | 125961-82-2.mol |  |
| | Tipelukast Chemical Properties |
| Melting point | 82-84°C | | Boiling point | 735.3±60.0 °C(Predicted) | | density | 1.22 | | storage temp. | Hygroscopic, Refrigerator, under inert atmosphere | | solubility | Chloroform (Slightly), Ethyl Acetate (Slightly) | | pka | 4.59±0.10(Predicted) | | form | Solid | | color | Off-White to Pale Beige |
| | Tipelukast Usage And Synthesis |
| Uses | Tipelukast a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model. | | Definition | ChEBI: Tipelukast is an aromatic ketone. | | Biological Activity | Tipelukast is a Leukotriene D4 (LTD4) receptor antagonist and an inhibitor of 5-lipoxygenase (5-LO) and also phosphodiesterases PDE3 and PDE4. It has been found to have antifibrotic and anti-inflammatory activity. Tipelukast has been investigated as a possible treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). | | in vivo | Fiftheen min after an aerosolized antigen challenge, and UNDW inhaled 5 min later into the guinea pigs, Tipelukast significantly alters the UNDW-induced bronchoconstriction[1]. Tipelukast (1 and 5 mg/kg) administered intravenously 15 min after antigen challenge reduces the propranolol-induced bronchoconstriction (PIB) in a dose-dependent manner in guinea-pigs[2]. | | IC 50 | LTD4: 6.41 (pA2, In guinea-pigs); LTE4: 6.45 (pA2, In guinea-pigs) |
| | Tipelukast Preparation Products And Raw materials |
|